Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
61. |
ECCT/09/03/01 | REMoxTB A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis |
Principal Investigator(s) 1. Evans Inyangala Amukoye Site(s) in Kenya Kibera D.O Health Centre |
View |
62. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) |
View |
63. |
ECCT/24/07/04 | AMC-114 A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings |
Principal Investigator(s) 1. Dr. Naftali Busakhala Site(s) in Kenya Moi University Clinical Research Center |
View |
64. |
ECCT/22/01/03 | lidERA A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
View |
65. |
ECCT/21/11/07 | lidERA A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORPOSITIVE, HER2-NEGATIVE EARLY BREAST CANCER |
Principal Investigator(s) 1. Fredrick Asirwa Chite Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
View |